Only amyloidogenic intermediates of transthyretin induce apoptosis.
about
Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue cultureMechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin AmyloidosisTafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascadeSelf-assembly of human latexin into amyloid-like oligomers.Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects.Uptake of aggregating transthyretin by fat body in a Drosophila model for TTR-associated amyloidosis.Interleukin-1 signaling pathway as a therapeutic target in transthyretin amyloidosis.Argpyrimidine, a methylglyoxal-derived advanced glycation end-product in familial amyloidotic polyneuropathy.An overview of drugs currently under investigation for the treatment of transthyretin-related hereditary amyloidosis.Fluctuation methods to study protein aggregation in live cells: concanavalin A oligomers formationInhibition of TTR aggregation-induced cell death--a new role for serum amyloid P component.Amyloidogenic and non-amyloidogenic transthyretin variants interact differently with human cardiomyocytes: insights into early events of non-fibrillar tissue damage.Amyloid in the cardiovascular system: a reviewDetection of high-molecular-weight amyloid serum protein complexes using biological on-line tracer sedimentation.Transthyretin: the servant of many masters.Inhibition of human transthyretin aggregation by non-steroidal anti-inflammatory compounds: a structural and thermodynamic analysisThe workings of the amyloid diseases.The effect of membranes on the in vitro fibrillation of an amyloidogenic light-chain variable-domain SMA.Prion-like propagation of protein aggregation and related therapeutic strategies.Human brain astrocytes mediate TRAIL-mediated apoptosis after treatment with IFN-gamma.Quantitative sensation and autonomic test abnormalities in transthyretin amyloidosis polyneuropathy.Square channels formed by a peptide derived from transthyretinPathophysiology and treatment of systemic amyloidosis.Understanding Pre-Eclampsia Using Alzheimer's Etiology: An Intriguing Viewpoint.Use of Noninvasive Imaging in Cardiac Amyloidosis.Oligomeric TTR V30M aggregates compromise cell viability, erythropoietin gene expression and promoter activity in the human hepatoma cell line Hep3B.Schwann cells contribute to neurodegeneration in transthyretin amyloidosis.Considerably Unfolded Transthyretin Monomers Preceed and Exchange with Dynamically Structured Amyloid Protofibrils.Potential of human γD-crystallin for hair damage repair: insights into the mechanical properties and biocompatibility.Prefibrillar aggregates of yeast prion Sup35NM and its variant are toxic to mammalian cells.Does the cytotoxic effect of transient amyloid oligomers from common equine lysozyme in vitro imply innate amyloid toxicity?A look into amyloid formation by transthyretin: aggregation pathway and a novel kinetic model.Unfolding and aggregation of transthyretin by the truncation of 50 N-terminal amino acids.Cytotoxicity of albebetin oligomers depends on cross-beta-sheet formation.FAP plasma-induced cellular toxicity.Familial and Senile Amyloidosis Caused by TransthyretinMulti-elemental analysis of serum and amyloid fibrils in familial amyloid polyneuropathy patients
P2860
Q24626477-D5EE962B-DD7E-4051-9E73-FB2A4407377BQ26764754-43E62A66-5DCA-4459-B2FF-8B31B10D8338Q27679360-95F2E82D-8EEB-4570-A802-664C4EAC0398Q30365734-E7C44036-B094-4B91-BAAC-BAB9925C4FDCQ33237201-D6B490EC-4334-411A-B1F5-31C270ACE1F1Q33778710-4029C335-81C4-423C-9580-F6F3C845614BQ34336131-6998FE97-FAE3-4AA5-BA59-8E8580134D14Q34336978-E738512C-A91B-4667-98ED-476B6D629337Q34428314-33924DED-F204-4841-B0A2-3F320D4C2EFBQ34536409-C4AFCBEA-F0D1-454E-949C-8B5B399652ABQ34580145-E62ED4B1-8EC9-42E1-916D-A6CBAE1D7C52Q34951860-F2B7C606-DD25-4994-AC45-43A4E694840CQ35588349-C4FBF491-4138-4C74-A6D5-CAE73D7EA93EQ35966921-E0596B6E-A507-470F-9B92-346080E0249EQ36763960-80504EDC-44BD-4C4E-A78F-1F0353EAEE00Q36790516-743968D5-9ACF-49CE-B7A6-C027B5C5578FQ36801112-27E8DF80-7DF3-41A6-980F-E24A36AB9F60Q36915963-23FA98AE-131C-4E39-8883-C0E6426E9220Q36983208-03E918BA-A847-4AD5-89DC-EE6D15829438Q37206824-2473E820-401E-4DE0-B87A-7B94A9DA4BC0Q37327568-50F9BC4D-AC25-4A33-9563-DC7438C5FF29Q37707886-C60DF4DC-B482-497C-9E79-8EB105659273Q38131710-B1267820-2F5D-481F-A2F1-92CEFB3ADB3EQ38638997-8ED20998-6A12-4759-BCF0-973C3C5F7AA5Q38834998-4A5FE0D4-70D8-4DD1-B6CB-CA2AA5875B61Q38862443-166B99B3-804F-499F-83CC-EF34DF55C3CAQ38908347-0D46556F-DC90-4E34-96A7-445DC3A1842FQ38991962-17126710-B5FC-4A53-8801-59B9A9B127A5Q39155157-3810C392-3045-4684-94B6-CAD55AFE1D50Q39461063-77022A49-A042-4A99-98AB-955EF139876EQ40485526-F7A2313F-5294-4950-B855-B3206898D468Q46770653-16149F38-2315-4AA2-AF99-26B7DD704025Q46794944-18ADBD87-E952-4C9F-BC66-E9C8F27516A7Q48567933-5DE0819E-C3EF-41AE-AB2C-C20039E99C46Q54156515-0B9A7B29-B994-4911-80A0-04FE2C85057BQ56031907-400FD805-4EF3-4B6B-BDDB-719984668015Q58255179-0D6F522E-5516-4ADD-8676-60103038F6D2
P2860
Only amyloidogenic intermediates of transthyretin induce apoptosis.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh
2002年學術文章
@zh-hant
name
Only amyloidogenic intermediates of transthyretin induce apoptosis.
@en
type
label
Only amyloidogenic intermediates of transthyretin induce apoptosis.
@en
prefLabel
Only amyloidogenic intermediates of transthyretin induce apoptosis.
@en
P2093
P1476
Only amyloidogenic intermediates of transthyretin induce apoptosis.
@en
P2093
Anders Olofsson
Ellen Holm Nielsen
Erik Lundgren
Karin Andersson
Sven-Erik Svehag
P304
P356
10.1016/S0006-291X(02)00465-5
P577
2002-06-01T00:00:00Z